$30M commitment supports development of therapies for viral infections

first_img From the lab to COVID front lines AbbVie will provide $30 million over three years and additional in-kind support leveraging AbbVie’s scientists, expertise and facilities to advance collaborative research and early-stage development efforts across five program areas that address a variety of therapeutic modalities:Immunity and immunopathology — Study of the fundamental processes that impact the body’s critical immune responses to viruses and identification of opportunities for therapeutic intervention.Led by Uli Von Andrian, Mallinckrodt Professor of Immunopathology in the Blavatnik Institute at HMS and program leader of basic immunology at the Ragon Institute of MGH, MIT, and Harvard; and by Jochen Salfeld, vice president, immunology and virology discovery at AbbVie.Host targeting for antiviral therapies — Development of approaches that modulate host proteins in an effort to disrupt the life cycle of emergent viral pathogens.Led by Pamela Silver, Elliot T. and Onie H. Adams Professor of Biochemistry and Systems Biology in the Blavatnik Institute at HMS; and by Steve Elmore, vice president, drug discovery science and technology at AbbVie.Antibody therapeutics — Rapid development of therapeutic antibodies or biologics against emergent pathogens, including SARS-CoV-2, to a preclinical or early-clinical stage.Led by Jonathan Abraham, assistant professor of microbiology in the Blavatnik Institute at HMS; and by Jochen Salfeld, vice president, immunology and virology discovery at AbbVie.Small molecules — Discovery and early-stage development of small-molecule drugs that would act to prevent replication of known coronaviruses and emergent pathogens.Led by Mark Namchuk, executive director of therapeutics translation at HMS and senior lecturer of biological chemistry and molecular pharmacology in the Blavatnik Institute at HMS; and by Steve Elmore, vice president, drug discovery science and technology at AbbVie.Translational development — Preclinical validation, pharmacological testing, and optimization of leading approaches, in collaboration with Harvard-affiliated hospitals, with program leads to be determined. $16.5 million awarded to projects to fight COVID Chan School’s Michael Mina urges federal regulatory approval, widespread use Technology developed at Harvard provides early boost to Mass. COVID testing Harvard University and AbbVie today announced a $30 million collaborative research alliance, launching a multi-pronged effort at Harvard Medical School (HMS) to study and develop novel therapies against emergent viral infections, with a focus on those caused by coronaviruses and by viruses that lead to hemorrhagic fever.This collaboration aims to rapidly integrate fundamental biology into the preclinical and clinical development of new therapies for viral diseases that address a variety of therapeutic modalities. HMS has led several large-scale, coordinated research efforts launched at the beginning of the COVID-19 pandemic.“A key element of having a strong R&D organization is collaboration with top academic institutions, like Harvard Medical School, to develop therapies for patients who need them most,” said Michael Severino, vice chairman and president of AbbVie. “There is much to learn about viral diseases and the best way to treat them. By harnessing the power of collaboration, we can develop new therapeutics sooner to ensure the world is better prepared for future potential outbreaks.”“The cataclysmic nature of the COVID-19 pandemic reminds us how vital it is to be prepared for the next public health crisis and how critical collaboration is on every level — across disciplines, across institutions, and across national boundaries,” said George Q. Daley, dean of Harvard Medical School. “Harvard Medical School, as the nucleus of an ecosystem of fundamental discovery and therapeutic translation, is uniquely positioned to propel this transformative research alongside allies like AbbVie.” Related MassCPR collaboration funds plans with promise to help in a year Cheap, frequent COVID tests could be ‘akin to vaccine,’ professor sayslast_img read more

How to become the next GFA President

first_imgWith the organisation of the Extraordinary Congress by the Ghana Football Association, the race to become the next President of the Ghana Football Association has become official.Those who are interested in the position will now wait for a date to be announced so that they can pick up forms, fill them, get the necessary signatures and support and file those forms and papers.So far, several people including former GFA officials, Wilfred Osei and George Afriyie, have stated their interest in replacing Kwesi Nyantakyi. Other individuals like Kurt Okraku, Dreams FC CEO and Asante Kotoko CEO, Kwame Kyei, have all said they would like to run Ghana football for at least the next four years.So how do I become GFA President?First of all, you must be affiliated to a club in the Ghana Football ecosystem to even get in the door before dealing with the fine print in the statutes.The draft statutes of the GFA, which were approved by the clubs at the Extraordinary Congress, state that anyone interested in the position must be a Ghanaian and must be of sound mind and “has not been detained as a person of mental disorder under any enactment.”What about my academics? One will need to have a first degree from a reputable university.What about if I do not have such a degree?If you have 7 years working experience in Sports Administration, you are good to go. In addition, having some good knowledge of rules and regulations that govern the Ghana FA, CAF and FIFA will certainly be very helpful.You must have also have very good practical experience in Management, Administration, Finance, or Corporate Governance. Running any entity will require these and the football association is no different body or association or company, if you choose to go by what the GFA is in the Registrar General’s records.What about my conduct?After the incidents of the Anas “Number 12” documentary which looked at corruption in Ghana football, it is not surprising that the Normalisation Committee has highlighted the need for the next GFA President to be one that will not stain the position or bring the local game into disrepute.Thus, if you want to be the next GFA boss, you should not “have been convicted of an offence involving fraud, dishonesty or moral turpitude” and you must be of “high moral integrity.”Is that all?No. After meeting all the above-stated requirements, you will face an integrity check and it is mandatory. All candidates are to  subject themselves to these checks and you will fail:-if you refuse to do so or you have been given a criminal conviction or disciplinary sanction by a state court;-if you have been found guilty by an Ethics Committee of the GFA, CAF or FIFA, a Commission of Enquiry  in Sports Administration or any sporting body with a sanction that affects how you will work as the GFA boss.What’s next?If you make it through all these processes, congratulations. You are now part of the race to become the next Ghana FA boss.So I win the elections. How long will be in office for?Per the new statutes that were approved at the Extraordinary Congress, you will serve for only two terms of four years each.That decision marked the end of the unlimited tenure rule that was in existence in the previous administration.Finally, when is the election?Even though there is no official date, the expectations are that the polls will take place later this month.The Normalisation Committee will have to end its tenure by September 30 and so, the elections must come off before then.last_img read more